Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01265576
Show Display Options
Rank Status Study
1 Active, not recruiting Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
Condition: HCC
Interventions: Drug: Sorafenib;   Drug: VT-122 (propranolol plus etodolac);   Drug: Placebo

Indicates status has not been verified in more than two years